PROJECT SUMMARY
Over 900,000 Americans are currently diagnosed with Ulcerative colitis (UC), an incurable inflammatory
bowel disease of complex etiology. UC is multifactorial, with genetics, microbiota, and uncontrolled immune
response leading to recurring colon ulcers and inflammation. With no defined cause, symptom management is
critical for patients with this chronic condition. A major endpoint for clinical treatment of UC and other
inflammatory bowel diseases is mucosal healing. Current UC therapeutics are predominated by anti-
inflammatories. To expand this arsenal, it is important to establish exactly how ulceration prevention and wound
healing occur such that these features can be enhanced in a targeted manner. Since our early published
discovery that Adenomatous Polyposis Coli (APC) protein has both cytoplasmic and nuclear functions, our
research has focused on mechanisms by which nuclear APC maintains normal intestinal homeostasis. To enable
our analysis, we generated mice with mutations in APC which compromise nuclear import. These Apc-mNLS
mice displayed decreased numbers of mucus-secreting goblet cells (GCs) and increased inflammation,
chemokine expression, and tissue damage in response to treatment with the colon irritant DSS compared to their
DSS-treated wild-type (WT) littermates. More recently, we published that in WT mice, DSS-treatment could
induce a subset of distal colon GCs to express elevated APC levels. Similarly, colon tissue from human CD
patients also displayed elevated APC protein level in most GCs, a phenotype not observed in unaffected tissue.
Based on these striking results, we wondered whether the elevated APC in UC colon might be a response
to ulceration in an attempt to restore normal colonic tissue homeostasis. As such, we sought to determine the
mechanistic basis for and cellular consequences of higher APC protein levels in UC tissue. RNA-seq analysis of
normal colon cells depleted for APC revealed a set of genes significantly downregulated. Cross-referencing this
list with APC ChIP-seq data as well as genes whose expression is altered in UC, we identified 7 genes with roles
in wound repair and mucus barrier production that are candidates for transcriptional regulation by nuclear APC.
We hypothesize that nuclear APC promotes wound repair and resolution of UC through driving
transcription of the major mucus barrier component MUC2 as well as specific wound repair mediators.
This hypothesis will be tested by addressing the following questions: Does nuclear APC 1) regulate transcription
of modulators of inflammation and wound repair (AIM1)? 2) promote colon wound healing (AIM2)? 3) promote
mucus layer generation and thereby impede microbial penetration, alter microbial composition and prevent
inflammation (AIM3)? Answering these questions is expected to establish nuclear APC as a key contributor to
wound repair, a finding that could ultimately be translated into new therapies for UC and other IBDs.